The efficacy of antiplatelet therapy (aspirin, P2Y12 and glycoprotein IIb/IIIa receptor antagonists) to prevent occlusive arterial events in patients with atherothrombotic disease is well established. Despite this, many patients continue to experience arterial events. Some patients exhibit failure of platelet inhibition as determined by ex vivo laboratory tests, a phenomenon termed "resistance" to antiplatelet therapy. Further studies must show clinical utility and cost-effectiveness of laboratory monitoring of antiplatelet therapy before it can be recommended in clinical practice.
COBISS.SI-ID: 26908121
Thrombophilia can be identified in about half of all patients presenting with venous thromboembolism (VTE). Thrombophilia screening has increased tremendously, but whether the results help in the clinical management of patients is uncertain. Here, current recommendations for thrombophilia screening in selected groups of patients and other high-risk subjects tested are reviewed. The methods for determination of the most common thrombophilic defects are also described. Finally, psychological, social and ethical dilemmas associated with thrombophilia screening are indicated.
COBISS.SI-ID: 21054190